BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.39 --0%
Revenue Growth %: +31.4%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
PGR, OMID, ACI, More
Revenue Growth %: +31.4%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
PGR, OMID, ACI, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.96, $0.61 better than the analyst estimate of $0.35. Revenue for the quarter came in at $712 million versus the consensus estimate of $662.05 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.10-$3.25, versus the consensus of $2.87. BioMarin Pharma sees FY2024 revenue of $2.75-2.82 billion, versus the consensus of $2.74 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Telefonica S.A. (VIV) to Neutral
- Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
- LTC Properties adds $95 million in two senior housing acquisitions
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
